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Abstract
Tumor necrosis factor (TNF) is a powerful pro-inflammatory cytokine and immuno-regulatory molecule, and
modulates susceptibility to musculoskeletal diseases. Several meta-analyses and replicated association studies have
implicated the minor ‘A’ variant within the TNF promoter single nucleotide polymorphism (SNP) rs361525 (-238A/G)
as a risk allele in joint related disorders, including psoriatic and juvenile idiopathic arthritis, and osteolysis after joint
arthroplasty. Here we characterized the effect of this variant on TNF promoter function. A transcriptional reporter,
encoding the -238A variant of the TNF promoter, resulted in 2.2 to 2.8 times greater transcriptional activation versus
the ‘G’ variant in murine macrophages when stimulated with pro-inflammatory stimuli. Bioinformatic analysis
predicted a putative binding site for thyroid hormone receptor (TR) for the -238A but not the -238G allele.
Overexpression of TR-α induced promoter expression 1.8-fold in the presence of the ‘A’ allele only. TR-α expression
both potentiated and sensitized the -238A response to LPS or a titanium particulate stimulus, whilst siRNA
knockdown of either THRA or THRB impaired transcriptional activation for the -238A variant only. This effect was
independent of receptor-ligand binding of triiodothyronine. Immunohistochemical analysis of osteolysis interface
membranes from patients undergoing revision surgery confirmed expression of TR-α within osteoclast nuclei at the
resorption surface. The ‘A’ allele at rs361525 confers increased transcriptional activation of the TNF promoter and
influences susceptibility to several arthritic conditions. This effect is modulated, at least in part, by binding of TR,
which both sensitizes and potentiates transcriptional activation of the ‘A’ variant independent of its endogenous
ligand.
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Introduction
Tumor necrosis factor (TNF) is a pleiotropic cytokine that has
powerful pro-inflammatory and immuno-regulatory functions.
TNF plays an important role in the pathogenesis of
musculoskeletal disease, and its blockade has become a major
therapeutic tool in their treatment [1]. Aseptic loosening due to
wear particle-induced osteolysis is the most common cause of
joint prosthesis failure requiring revision surgery [2]. TNF plays
a pivotal role in osteolysis, inducing osteoclastogenesis by both
RANK/RANKL dependent and independent pathways [3-5].
TNF p55 receptor null transgenic mice show resistance to wear
particle-induced bone resorption [6], and anti-TNF therapy
using Etanercept reduces titanium particle-induced osteoclastic
bone resorption both in-vitro and in-vivo [7,8].
The gene encoding TNF is located within the highly
polymorphic major histocompatibility complex region on
chromosome 6p21, 3 [9]. Several meta-analyses have linked
carriage of the minor ‘A’ allele of the G/A single nucleotide
polymorphism (SNP) at the -238 position (rs361525, global
minor allele frequency 5% in 1000 Genomes dataset) of the
TNF promoter with increased susceptibility to musculoskeletal
diseases, including Behçets disease [10], systemic lupus
erythematosus [11], juvenile idiopathic arthritis [12], and
psoriatic arthritis [13]. We have previously shown that rs361525
is also a susceptibility locus for osteolysis in patients after total
hip arthroplasty [14]. This association has been replicated in an
independent population by Gallo et al [15]. In both studies
carriage of the ‘A’ allele associated with both increased
susceptibility to, and severity of osteolysis. In support of a
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functional role in-vivo for the ‘A’ variant at this site Sapey et al.
[16] found in a longitudinal study of bronchitis patients that
those carrying rs361525 had more chronic bronchitis and a
greater annual decline in lung function. Bioactive TNF protein
levels in their airway secretions were 100-fold higher than non-
carriers, and their lung secretions contained more IL-8 and
myeloperoxidase, consistent with greater downstream
inflammation.
Genetic variation within a gene promoter can influence gene
activity, SNPs in the transcribed region can impact on pre-
mRNA stability and can also lead to mutations which alter the
ability of protein to bind to its substrates or inhibitors as well as
changing sub-cellular localization of proteins, and thereby
modulate disease susceptibility [17]. Several transcription
factor binding sites exist within the TNF promoter, including
NFκB, Ets, NF-AT, AP-1, STAT1, and LITAF. Despite the
considerable published literature, the contribution of these
regulatory elements to TNF activation and expression is
incompletely understood [18], and the functional relevance of
rs361525 on TNF promoter activity in the setting of
musculoskeletal disease remains unclear.
The aim of this study was to determine the functional effect
of the rs361525 variant on TNF promoter transcriptional
activation using an in-vitro macrophage model, in response to a
variety of clinically-relevant stimuli. Clearer understanding of
the molecular mechanisms by which this variant confers
susceptibility to diseases linked to this locus, including
osteolysis, Behçets disease, systemic lupus erythematosus,
juvenile idiopathic arthritis, and psoriatic arthritis, may lead to
novel therapeutic strategies in their treatment.
Results
The ‘A’ variant of rs361525 enhances the
responsiveness of TNF promoter to TLR-mediated
activation
In order to test the functional importance of the ‘A’ versus ‘G’
variation in rs361525, luciferase reporters were developed,
under the control of the TNF promoter, encoding for each of
these variants. In order to rule out the influence of other SNPs,
the promoter allele, encoding for the ‘G’ variant at -238 was
subjected to sited directed mutagenesis, generating the ‘A’
allele (for the full promoter sequence, see Figure 1).
Responses against a range of concentrations for Gram
negative (LPS) as well as Gram positive (LTA) bacterial cell
wall components were evaluated, using Raw 264.7 cells that
were transiently transfected by these reporters (Figure 1).
Whilst both TNF promoter variants were induced by these
stimuli, the construct containing the ‘A’ variant showed
consistently higher response to both LPS and LTA (Figure 1).
The ‘A’ variant of rs361525 encodes for a putative
thyroid hormone receptor (TR) binding site
In-silico analysis of the sequence surrounding rs361525
predicted a binding site for thyroid hormone receptor (TR) for
the ‘A’ allele and a binding site for Sp1 for the ‘G’ allele (Figure
2A). Next, we characterized the potential involvement of TR in
the control of TNF expression in Raw 264.7 macrophage like
Figure 1.  TNF promoter containing the ‘A’ variant of
rs361525 has an augmented response to TLR4 and TLR2
ligands, compared to the -238G variant.  Raw 264.7 cells
were transiently transfected with firefly-luciferase reporters
under the control of the ‘A’ or the ‘G’ variants of the TNF
promoter, and co-transfected with a constitutive Renilla-
luciferase reporter. Transfected cells were stimulated with the
stated concentration of lipopolysaccharide (LPS, TLR-4 ligand;
panel A) or Lipoteichoic acid (LTA, TLR-2 ligand; panel B) for 6
hours. A representative of four experiments is shown. Results
were analyzed by two-way ANOVA with a Bonferroni post-test.
* p<0.05, *** p<0.001, **** p<0.0001.
doi: 10.1371/journal.pone.0076034.g001
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cells. TR proteins are encoded by two genes, THRA and
THRB, which are expressed in primary macrophages. RT-PCR
analysis revealed that both of these genes are expressed in
this cell line (Figure 2B), making it a suitable in vitro system to
investigate the impact of the receptor in TNF expression. Next,
we demonstrated that the “A” allele interacts with TR, by
analysis with an electrophoretic mobility shift assay (GMSA)
(Figure 2C). A radiolabeled DNA probe encoding the "A" allele
showed evidence of protein binding when incubated with
nuclear extracts, and the specificity of the observed shifted
complex was confirmed by competition with excess cold probe.
Incubating of the binding reaction in the presence of anti-TRβ
polyclonal antibody resulted in a super-shifted complex
consistent with binding of the antibody to a TRβ protein-DNA
complex.
Overexpression of TR-α selectively induces the TNF
promoter containing the ‘A’ variant of rs361525 and is
independent of thyroid hormone binding
In order to assess the potential interaction between the TR
and the TNF promoter in macrophages, Raw 264.7 cells were
transiently transfected with the ‘A’ or the ‘G’ variant of the TNF
promoter driven luciferase reporter in the presence or absence
of the TR-α expression vector. Whilst expression of an
increasing dose of TR-α had no effect on the activity of the ‘G’
allele, the reporter driven by the ‘A’ allele was induced in a
dose-dependent fashion (Figure 3A). Next, the impact of TR-α
expression on the LPS induced activation of the TNF -238A
allele was investigated. Induction of the reporter was
augmented as well as sensitized in the presence of co-
expressed TR-α Figure 3B). Half max. reporter activation was
achieved at ~0.5ng LPS in the presence of co-expressed TR-α
versus 10ng LPS in controls, suggesting that binding of this
Figure 2.  Bioinformatic analysis predicts a putative binding site for thyroid hormone receptors for the ‘A’ variant at
rs361525.  Sequences surrounding the -238 A/G polymorphism were analysed by AliBaba 2.1 (http://www.gene-
regulation.com/pub/programs/alibaba2/index.html) to predict putative allele-specific transcription factor binding sites (Panel A). The
polymorphic nucleotides are capitalised and the binding sites spanning this position are highlighted in bold.
The expression of THRA and THRB in Raw264.7 cells was confirmed by RT-PCR (Panel B). Total RNA was purified from control,
LPS stimulated (40 ng/ml, 6 hrs) or LTA stimulated (5 µg/ml, 6 hrs) cells, reverse transcribed and expression was detected by gene
specific PCR primers (THRA: 480 bp product, THRB: 430 bp product).
EMSA was performed to demonstrate binding of TR to the “A” variant of rs361525 (Panel C). Specificity of binding was ascertained
by competition with a 100-fold molar excess of cold DNA fragments added to the reaction mixture (lane 3). For super-shift assay,
the nuclear extract were incubated with an anti-TRβ polyclonal antibody.
doi: 10.1371/journal.pone.0076034.g002
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protein to the TNF promoter may contribute to the inducibility,
as well as to the sensitivity, of TNF activation.
Thyroid hormone receptors are localized in the cell nucleus.
However, they are thought to be complexed with co-repressor
proteins in the absence of ligand binding, thus unable to
activate their targets in most cases. Therefore, the impact of
thyroid hormone (as the biologically active hormone
triiodothyronine/T3) on the activity of TNF promoter was
assessed in Raw 264.7 cells. Cells were transiently transfected
with the TR responsive reporter driven by the -238A allele and
Figure 3.  Overexpression of TR-α induces the activation of
the TNF promoter containing the ‘A’ variant of rs361525 in
synergy with TLR-4 mediated promoter induction, and is
independent of thyroid hormone binding.  Raw 264.7 cells
were transiently transfected with firefly-luciferase reporters
under the control of the ‘A’ or the ‘G’ variants of the TNF
promoter, at position -238 and co-transfected with the stated
amount of TR-α expression plasmid (Panel A). Raw 264.7 cells
were transiently transfected with the firefly-luciferase reporter
under the control of the ‘A’ variant of the TNF promoter, and
co-transfected with 30ng of TR-α expression plasmid (Panel B).
Transfected cells were stimulated with the stated concentration
of lipopolysaccharide (LPS) for 6 hours. Raw 264.7 cells were
transiently transfected with the firefly-luciferase reporter under
the control of the ‘A’ variant of the TNF promoter and
stimulated with the stated concentration of thyroid hormone
(TH) and LPS for 6 hours (panels C and D). Results for panels
A and B were analyzed by two-way ANOVA with a Bonferroni
post-test, for panels C and D by one-way ANOVA with a
Bonferroni post-test. *** p<0.001, **** p<0.0001.
doi: 10.1371/journal.pone.0076034.g003
the effect of increasing dose of T3 on promoter activity (Figure
3C) and the impact on LPS induced reporter activation (Figure
3D) was investigated. Our results showed that T3 does not
influence activation of the TNF promoter, suggesting that the
action of TR encoded by the -238A variant is independent of its
endogenous ligand.
siRNA knockdown of TR mRNA selectively impairs the
activity of the TNF promoter containing the ‘A’ variant
of rs361525
Next, we wished to clarify whether TR expression is
necessary for the full activation of TNF by LPS or LTA. Raw
264.7 cells were transfected with luciferase reporter driven by
either the -238A or the -238G variant and induced reporter
activity was measured. The impacts of pools of four siRNAs
against THRA and THRB versus non-targeting (siNC) on
reporter activity were compared under basal and stimulated
conditions (Figure 4). Efficiency of the siRNA knockdown was
verified by qRT-PCR (Figure 2). In agreement with the in-silico
predictions and our TR-α over-expression results, selective
inhibition of -238A transcriptional activity was observed in TR
knockdown for basal expression, and following LPS or LTA
stimulation (Figure 4A, C and E). Such inhibition was not
observed for the construct containing the ‘G’ allele (Figures 4B,
D and 4F). Indeed, a small increase in the activity of the ‘G’
allele was observed in response to siTR treatment. Whilst the
reasons for this are unclear, it is possible in addition to
activating TNF expression via the -238 ‘A’ allele, TR proteins
may also interact with other factors, that are (directly or
indirectly) involved in the control of TNF expression and that
the net effect of some of these interactions may be inhibitory.
Titanium particles induce a TR-dependent activation of
the TNF promoter containing the ‘A’ variant of rs361525
In periprosthetic osteolysis macrophage activation results
from ingestion of particulate wear debris from the prosthesis
surfaces, an effect that is potentiated by absorption of bacterial
debris onto the particle surface [19,20]. We investigated the
interaction between titanium particles, TNF promoter activation
and the TR. In line with previous studies [21], commercially
pure titanium particles, but not endotoxin-stripped ones, were
able to activate the luciferase reporter driven by the -238A
allele of the TNF promoter (Figure 5A). The contribution of the
TR to this was demonstrated by a sensitized response in the
presence of overexpressed TR (Figure 5B), as well as by an
impaired activation of the -238A but the -238G allele in cells
where TR-α or β were knocked down using siTHRA and
siTHRB (Figure 5C vs. D).
TR-α is expressed in clinical osteolysis membrane-
bone interface tissue retrieved from patients
Macrophage/osteoclasts are key players in the progression
of osteolysis, in part due to their ability to express inflammatory
cytokines, including TNF. Membrane-bone biopsied previously
retrieved from patients undergoing revision surgery for
confirmed aseptic loosening were stained for TR-α, to confirm
whether the TR is expressed in clinically relevant tissues in a
disease that is modulated by allelic variance at rs361525.
A TNF Promoter SNP Controls Gene Activation
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Immuno-staining staining of the interface tissues confirmed the
presence of TR-α protein was expressed within the nuclei
resorbing osteoclasts at the bone surface (Figure 6A).
Discussion
Previous replicated studies have implicated the TNF locus
rs361525 in susceptibility and severity of many musculoskeletal
diseases. Using in-silico analysis we identified a TR binding
site in the presence of the ‘A’ but not the ‘G’ variant at this
locus. Subsequent assays demonstrated that overexpression
Figure 4.  Knockdown of TR-α and TR-β mRNA impairs
basal and TLR induced expression of the TNF promoter
containing the ‘A’ variant of rs361525.  Raw 264.7 cells were
transiently transfected with firefly-luciferase reporters under the
control of the ‘A’ (panels A-C) or the ‘G’ (panels D-F) variants
of the TNF promoter and co-transfected with non-targeting
(siNC), THRA or THRB targeting siRNAs, respectively.
Transfected cells were stimulated with the stated concentration
of lipopolysaccharide (LPS, panels B and E) or Lipoteichoic
acid (LTA, panels C and F) for 6 hours. Results were analyzed
by one-way ANOVA with a Bonferroni post-test. * p<0.05, **
p<0.01, *** p<0.001.
doi: 10.1371/journal.pone.0076034.g004
of the TR-α, which predominates in bone [22], increased
transcriptional activation of the ‘A’ variant of the TNF promoter
through both the sensitization and potentiation of the signal.
This effect was observed with stimulation using both common
toll-like receptor agonists and a particulate stimulus relevant to
periprosthetic osteolysis, and was independent of the
receptor’s binding to its endogenous ligand. Finally, we
confirmed that TR-α protein is expressed in the nuclei of
osteoclasts at resorption surfaces in biopsies of osteolytic
tissue taken from patients undergoing revision arthroplasty
surgery.
Studies in primary human monocytes have shown that
inflammatory cytokine responses in patients susceptible to
osteolysis are greater than those in patients who do not
demonstrate this susceptibility [23], and that TNF induction
shows marked inter-individual variation [24]. Raabe et al., in a
series of experiments using LPS-stimulated RAW 264.7 cells
showed that control of TNF production in this system is thought
to occur primarily at the transcriptional and not the translational
level [25]. Bayley et al. constructed a series of mutants in a
large 1176bp fragment of the TNF promoter which replaced the
SNPs at -376, -308, -244 and -238 with 10bp link scan
sequences to abrogate binding motifs, and found that the
-244/-238 region, but not the -308 and -376 regions, modulate
transcriptional regulation in some cell lines [26].
Both the α and β isoforms of the TH are expressed in bone,
and knockout mice for THRA and THRB have a bone
phenotype. TR-α knockout have delayed bone maturation, but
a high bone mass phenotype on aging, whilst TR-β knockout
mice have anabolic actions during growth but rapid bone loss
in maturity [27]. Thyroid hormone receptors mediate the bone
resorptive action of TH in adult mice, and this effect is
mediated by the TR-β [28]. Our data indicates that TR-α may
modulate a bone loss phenotype through enhanced TNF
induction independent of TH. In contrast, Sp1 binding sites are
occupied by a family of ubiquitously expressed transcription
factors, that control of expression for “house-keeping” genes
and hormones and is thought to play a role in the regulation of
early development and metabolism [29], in-keeping with our
observation that the ‘G’ allele at the rs361525 locus is relatively
non-inducible. Our findings suggest a functionally relevant
novel mechanism for modulating transcriptional activation of
the TNF promoter (Figure 6B), and that TR may modulate
responses to agonists signaling through TLR-2, TLR-4, and the
inflammasome, which are important inducible pathways in
inflammatory arthritis and periprosthetic osteolysis [30].
Previous studies describing the function of polymorphisms
within the TNF promoter have produced inconsistent results
[31,32]. TNF lies within a highly polymorphic region within the
MHC that contains many inflammatory and immune response
related proteins [33]. There is also extensive linkage
disequilibrium between SNPs across the MHC. Such allelic
confounders and cell-type and stimulus specific effects are
likely to contribute to the variable findings. We aimed to
overcome such effects by investigating the impact of a single
polymorphism in “isolation”, using plasmid based,
transcriptional reporters. We employed several, physiologically
relevant TLR agonists in combination with overexpression and
A TNF Promoter SNP Controls Gene Activation
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knockdown of endogenous TR’s to generate a complementary
set of experiments with high internal consistency. However,
these experiments also have limitations. Firstly, we used an
established cell line rather than primary cells. However, whilst
osteolysis is principally a macrophage-driven process, thus
making the Raw 264.7 macrophage cell line an appropriate
model to use, the macrophages within a joint are highly
differentiated; there are multinucleate osteoclasts, resident
tissue macrophages and monocytes all of which are different
from an in-vitro murine macrophage. Also, the experiments
investigated the impact of human promoter variants in a
murine-derived macrophage cell line so the expression activity
of the promoter may not be represented as accurately as it
would be in a human cell line. Nevertheless, the sequence
specificity of transcription factors is unlikely to differ between
human and murine systems. Given that the promoter region of
the TNF gene is highly variable, it is conceivable that other
SNPs, and their impact on the binding of transcription factors
may modulate the ability of TR to bind to -238. This could be
addressed by an extensive ChIP analysis, which will be the
focus of future studies.
In conclusion, we found that the rs361525 locus influences
transcriptional activity of TNF promoter in response to both
TLR agonists and clinical relevant particles. Our data indicate
that the ‘A’ allele creates a functionally-active TR binding site.
We confirmed that this receptor is expressed within osteoclast
cells within osteolytic lesions in arthroplasty patients
undergoing revision surgery. These findings may also have
functional relevance for other inflammatory joint conditions
under TNF control and modulated by rs361525, including
ankylosing spondylitis, systemic lupus erythematosus, juvenile
idiopathic arthritis, and Behçets disease.
Materials and Methods
Ethics
This study was approved by Oxford NRES Research Ethics
Committee C, and by Sheffield Musculoskeletal Biobank. The
study was conducted according to the principles expressed in
the Declaration of Helsinki, and all patients provided written,
informed consent prior to participation
Cell lines and transient transfections.  Raw 264.7 cells
were purchased from ATCC (Cat. No: TIB-71, LGC Standards,
Teddington, UK) and maintained according to the suppliers’
recommendations. All transfections described in this study
were performed in 96 well plates, using three biological
replicates. For transient transfection, Dharmafect Duo
Figure 5.  Titanium particles bind LPS and can activate TNF promoter containing the ‘A’, but not the ‘G’ variant of
rs361525.  Raw 264.7 cells were transiently transfected with the firefly-luciferase reporter under the control of the ‘A’ (panels A-C)
or the ‘G’ variant (panel D) of the TNF promoter, and co-transfected with 30ng of TR-α expression plasmid (panel B) or with non-
targeting (siNC), THRA or THRB targeting siRNAs, respectively (panels C-D). Transfected cells were stimulated with the stated
concentration of Ti particles (panels A-B) or 4500 particles/cell (panels C-D) for 6 hours. Results were analyzed by one-way ANOVA
with a Bonferroni post-test. ** p<0.01, *** p<0.001.
doi: 10.1371/journal.pone.0076034.g005
A TNF Promoter SNP Controls Gene Activation
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(Dharmacon, Inc., Chicago, IL) was used, as recommended by
the manufacturer (100 ng/well plasmid DNA, including 75 ng
reporter DNA (containing a mixture of the TNF promoter-Firefly
luciferase and the EF1 promoter-Renilla luciferase reporters)
and 25 ng cDNA expression plasmid (or empty vector)/well and
10 pmol siRNA). After transfection, cells were incubated in 100
µl of complete medium (DMEM+10% heat inactivated fetal
bovine serum). 16 hours after transfection, agonists were
added in 5 µl of PBS to the medium. Cells were lysed 6 hours
after stimulation and luciferase assays performed with Dual
Figure 6.  TR-α is expressed in osteoclasts at the
osteolysis-membrane interface in patients with failed hip
replacement and proposed mechanism of TR action on
TNF promoter activation.  Panel A: Photomicrographs of
osteolysis interface membrane-bone sections from 2
representative patients (total n=6) and stained for anti-thyroid
TR-α1 and TR-α2, demonstrating nuclear staining of
osteoclasts lying on bone surfaces.
Panel B: LPS induced activation of the -238A TNF promoter
allele is facilitated by the binding of TR. In contrast, the SP1
site in the -238G allele could be occupied by SP1 even in the
absence of TLR stimulus, resulting in a less inducible
expression of the TNF promoter.
doi: 10.1371/journal.pone.0076034.g006
Luciferase Assay (Promega Corp., Madison, WI). Each
experiment was performed at least three times, with similar
results.
Plasmids
Two firefly luciferase reporters (containing either the A or the
G allele of rs361525) were used in this study, based on the
pGL3.basic vector (Promega Corp.) containing a 691 bp
fragment (-585 to +106) of the gene TNF. The TNF inserts
were fully sequenced to confirm that aside from the rs361525
A/G polymorphism, the sequences were identical. An EF1-
driven Renilla luciferase reporter was used, as described
previously. For overexpression of mouse TR-α, a cDNA clone
was isolated and sequenced from a pSPORT6 based custom
cDNA expression library. Pools of four siRNAs against mouse
thyroid hormone receptor genes THRA and THRB (Smartpool
Target Plus) were purchased from Dharmacon, Inc. and used
according to the manufacturer’s recommendation.
PCR
RT-PCR was used in order to detect expression of THRA
and THRB in Raw 264.7 cells, using standard protocols.
Primers to amplify the respective thyroid hormone receptor
(TR) cDNAs were:
TR-α: sense 5’- ATGCCGGACGGAGACAAGGTAGAC -3’;
TR-α: antisense 5’- TTGGGCCAGAAGTGCGGAATGTT -3’;
TR-β sense: 5’- AAGTCGGGCTGCCTGAGTTCTA -3’;
TR-β antisense: 5’- TCTAATGGGGCTTCTTCCTTCTAT -3’
Agonists
Lipopolysaccharide (LPS), lipoteichoic acid (LTA) and
triiodothyronine (T3) were purchased from Sigma Aldrich
(Sigma Aldrich, Cambridge, UK). Titanium particles were
supplied as a gift from Dr EM Greenfield (Case Western
Reserve University, Cleveland, OH). Two types of particles
were used; commercially pure (cp) endotoxin free titanium
particles (LPS concentration 1.5 EU/ml), and endotoxin-
stripped Ti particles (0 EU LPS/ml). The protocols for
preparation of the particles are described in detail elsewhere,
as are their size characteristics and ability to induce cytokine
production in mononuclear cells [34,35].
Clinical osteolysis membrane-bone interface tissue
retrieval and Immunohistological analysis
Membrane-bone biopsies in cases of periprosthetic
osteolysis are routinely retrieved at our institution for diagnostic
purposes, and subsequently retained in a clinical histological
archive. Sections from 6 anonymized patients were retrieved
from the diagnostic archive for this analysis following National
Research Ethics Committee and local Biobank approval. Four
micron sections were deparaffinized in xylene, hydrated
through graded alcohols. Sections were treated with an
aqueous solution of 3% H2O2 to block endogenous peroxidase
staining. Antigen retrieval was carried out by trypsin dilution.
The sections were incubated with blocking serum followed by
overnight at 4°C in primary antibody (rabbit polyclonal anti-
thyroid hormone receptor alpha 1+2, Abcam, Cambridge, UK).
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A secondary goat anti rabbit antibody (Vector Labs Ltd,
Peterborough, UK) was added to the sections, followed by an
Avidin Biotin Complex solution (Vector Labs Ltd). For
visualization, a DAB solution (Vector Labs Ltd) and a
haematoxylin counterstain were added to the sections.
EMSA
Electric Mobility Shift Assay was performed according to the
method of Lee et al [36]. Complementary oligonucleotides of
the following sequence were synthesized and end labelled with
[ϒ32P] dATP and polynucleotide kinase prior to annealing:
TRAF - 5' -cccccctcggaatcAgagcagggaggatgg, TRAR - 5' -
ccatcctccctgctcTgattccgagggggg. Protein extract were isolated
from human coronary artery smooth muscle cells, as described
previously [36] and analysed by 4% native polyacrylamide gel
electrophoresis in 0.5x TBE buffer. Specificity of binding was
ascertained by competition with a 100-fold molar excess of cold
DNA fragments added to the reaction mixture. For super-shift
assay, the nuclear extract was incubated with an anti-TRβ
polyclonal antibody (PA1-213, clone TRβ-62, Affinity
Bioreagents, Golden, CO) at 4 °C for 2 h before addition to the
reaction mixture.
Supporting Information
Figure S1.  The nucleotide sequence of the promoter
region of the TNF gene used in this study has been
verified by sequencing. Polymorphic residues that have been
previously been studied by Bayley at all as part of the same
haplotype are highlighted (bold, italics, underlined). The -238
A/G variant that was the focus of this work is highlighted in red.
(TIFF)
Figure S2.  Reproducible knockdown of Thra and Thrb was
achieved (n=3) in Raw 264.7 cells, as verified by gene
specific Taqman qRT-PCR (ABI). Mean expression values
(relative to beta-actin levels) were used and expressed as
normalized to control treated (siNC) samples. Experimental
conditions were identical to those, used in experiments that are
presented in Figures 4-5.
(TIFF)
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